European Parkinson’s specialists issued consensus recommendations for the newly approved dual-release levodopa formulation IPX203, aimed at patients experiencing motor fluctuations. The guidance positions the formulation within existing treatment decision-making for optimizing symptom control while maintaining tolerability. For clinicians and payers, consensus recommendations are often the fastest pathway to uptake after regulatory approval, especially when they address practical questions—timing, patient selection, and how to compare against existing levodopa strategies. The key development watch will be how real-world dosing patterns and outcomes compare with phase-based expectations, particularly for patients transitioning from standard immediate-release levodopa regimens.